A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age
Journal article published in Vaccine and co-authored by PATH's Yuxiao Tang, Renee Holt, and Bruce Innis.
Publication date: November 2022